Basilea Pharmaceutica (BSLN) Q2 2026 Earnings Report

The call presented a strongly positive operational and financial picture: double-digit revenue growth, a materially higher operating profit, strengthened cash position, increased non-dilutive funding, and clear pipeline progression (two Phase III assets and new first-in-human study). Management raised full-year guidance and reiterated multi-year value creation (Agenda 2030). Key challenges are execution and timing risks around late-stage clinical readouts and regulatory clarity, increased R&D spend and near-term operating expense pressure, working capital timing effects on cash flow, and a convertible bond maturing in 2027. On balance, the positive commercial momentum, funding awards, guidance upgrades and pipeline advancement outweigh the near-term costs and timing uncertainties.

Basilea updated FY2026 guidance, now expecting total revenue to grow by approximately 15%, with Cresemba- and Zevtera-related revenues rising to around CHF 210 million (up from prior guidance of ~CHF 200 million) and delivering an expected cash contribution of ~CHF 180 million; the company forecasts CHF 125 million in royalties, CHF 35 million in milestone payments and CHF 50 million in product revenue for the year. Driven by the higher revenue outlook, operating profit guidance was raised to an increase of ~40% year‑on‑year (previously ~20%), equivalent to a rise from about CHF 62 million to ~CHF 72 million, while investments into R&D are still expected to increase by ~20% year‑on‑year. Management also highlighted strong balance‑sheet and funding metrics that underpin the guidance: cash and cash equivalents (plus restricted cash) of CHF 176 million, a net cash position that doubled to CHF 105 million, and substantial nondilutive R&D support with >USD 440 million committed, ~USD 165 million awarded to date (including USD 61 million in H1 2026) and over USD 350 million of potential funding still available.